Castration Resistant Prostate Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)
Published: 2024 February 26
SKU : PH4193
180 pages
Report Summary
Table of Contents
List of Tables & Figures
Buy this report
Single User
$4350
Multiple User
$4850
Enterprise User
$7850
Request new version
FAQ’s
What is the expected growth rate of the castration-resistant prostate cancer treatment market?
The global castration-resistant prostate cancer treatment market is expected to grow at a CAGR of 9% during the forecast period (2024-2031).
What are the emerging therapies driving market growth?
Emerging novel therapies for the treatment of castration-resistant prostate cancer, such as apalutamide and darolutamide, are expected to drive market growth. These drugs have shown promise in prolonging metastasis-free survival in patients with non-metastatic CRPC.
Who are the major players in the castration-resistant prostate cancer treatment market?
Major key players in the castration-resistant prostate cancer treatment market include Active Biotech AB, Diagnocure, Glaxosmithkline PLC, Northwest Biotherapeutics, Millennium Pharmaceuticals, Hologic, Spectrum Pharmaceuticals, Abbott Laboratories, and Bayer Healthcare Pharmaceuticals.
Which region holds the largest market share for castration-resistant prostate cancer treatment?
North America dominates the market due to its large prostate cancer population, developed healthcare infrastructure, and increasing awareness.